Pfizer Inc. (PFE) Stock
NYSEPFE has an Alpha Score of 50 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 61 members of Congress disclosed 195 trades in PFE since 2014: 79 purchases and 116 sales, most recently Tommy Tuberville (sale, Jun 8, 2026). 6 of the hedge funds AlphaScala tracks reported PFE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $149.08M. Company insiders reported 3 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 39.1 and its net margin 6.8% (key statistics as of Oct 22, 2026).
What is PFE's Alpha Score?
How it works →Alpha Score of 50 reflects moderate overall profile with strong momentum, moderate value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Pfizer Inc. (PFE)?
Most recent: Tommy Tuberville (sale, Jun 8, 2026); records start Apr 24, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tommy Tuberville R-AL · Senate | 2026-06-08 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-24 | sale | $50k – $100k |
| Gil Cisneros D-CA · House | 2026-03-13 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-02-10 | purchase | $1k – $15k |
| French Hill R-AR · House | 2025-12-31 | sale | $100k – $250k |
| Gil Cisneros D-CA · House | 2025-12-19 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-08-05 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded PFE, with filing lags →Which hedge funds own PFE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 6.19M | $149.08M | -16% |
| D.E. Shaw David Shaw | 5.41M | $130.38M | -57% |
| Marshall Wace | 802K | $19.32M | -95% |
| Millennium Management Israel Englander | 556K | $13.39M | +477% |
| Bridgewater Associates Ray Dalio | 180K | $4.34M | NEW |
| Hussman Investment Trust John Hussman | 42K | $1.01M | n/a |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Pfizer Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 12, 26 | Bourla Albert | Chairman & CEO | BUY | 38.0K | $1.0M |
| Aug 5, 26 | Buckley Mortimer J | Director | BUY | 37.6K | $960K |
| Aug 5, 26 | Blaylock Ronald E | Director | BUY | 39.2K | $999K |
| Aug 5, 26 | Damico Jennifer B. | SVP & Controller | SELL | 3.3K | $83K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are PFE's key statistics?
Key statistics as of Oct 22, 2026
How does PFE's valuation compare with the Healthcare sector?
| Metric | PFE | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 39.1 | 27.0 | 96 |
| Net margin | 6.80% | 5.92% | 136 |
| Return on equity | 4.89% | 7.18% | 155 |
| Dividend yield (payers) | 5.38% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 1, 2026). P/E excludes loss-making companies.
What did Pfizer Inc.'s latest SEC filings say?
Latest 1Pfizer Reports 2025 Financial Results and Strategic Restructuring Initiatives
Pfizer Inc. filed its 2025 10-K, detailing a year of significant portfolio adjustments and cost-management programs. The company continues to navigate the integration of major acquisitions, including Seagen, while executing multiple restructuring plans aimed at optimizing its manufacturing footprint and overall cost base. Financial operations in 2025 were marked by ongoing investments in research and development, particularly in the biopharma segment, and the management of various collaborative arrangements and licensing agreements. The company reported activity related to its equity method investments, including divestitures of its stake in Haleon. Pfizer also entered into new strategic agreements, such as the November 2025 arrangement with Metsera, involving payments linked to clinical trial milestones and regulatory approvals. The company maintains a focus on its core biopharma operations, with ongoing efforts to streamline research and development and manufacturing processes. Asset impairments and restructuring charges remain a component of the company's financial profile as it aligns its cost structure with current strategic priorities. The filing highlights the company's reliance on a concentrated portfolio of products, with the top eleven to twelve products representing a significant portion of its revenue base. Management continues to monitor the impact of these restructuring programs on its long-term financial health and operational efficiency.
- ›Executed multiple cost-realignment and manufacturing optimization programs within the Biopharma segment.
- ›Completed divestiture activities related to equity method investments in Haleon throughout 2025.
- ›Entered into a strategic agreement with Metsera involving milestone-based payments for clinical and regulatory progress.
- ›Continued integration of Seagen, including associated restructuring and acquisition-related costs.
- ›Reported ongoing asset impairments and restructuring charges related to research and development and manufacturing.
- ›Maintained high product concentration, with the top twelve products accounting for a significant revenue share.
AlphaScala analysis on PFE
Latest 1PFE price chart
Powered by TradingViewWhat does Pfizer Inc. do?
Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeting developed and emerging markets to advance wellness, prevention, treatments, and cures for the most feared diseases. Operating in the health technology sector, specifically pharmaceuticals: major, Pfizer Inc. addresses critical areas such as oncology, rare diseases, internal medicine, inflammation and immunology, vaccines, anti-infectives, gene therapy, medicinal sciences, and precision medicine. Notable advancements include acquisitions like Global Blood Therapeutics in 2023 to bolster its biopharmaceutical portfolio, alongside recent clinical trial successes in prostate cancer, lung cancer, and bladder cancer therapies. With approximately 81,000 employees, Pfizer Inc. generates substantial revenue, reported at $63.63 billion for the fiscal year, and maintains a significant presence in the global market through innovative pipelines and partnerships.